Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup. UC surveillance patients with negative cystoscopy and long-term follow-up with outcomes were analyzed for recurrence risk (validation cohort). The cohort was subdivided based upon the key clinical demographics of primary tumor grading and intravesical therapy (IVT) history. **(A)** LG (n = 27), **(B)** HG (n = 28), **(C)** IVT-naïve (n = 30), and **(D)** Prior IVT (n = 25) patients were analyzed. Kaplan-Meier curves for recurrence-free survival by UroAmp predicted risk are shown for each subgroup.